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Abstract
Problem: Embryo implantation and placentation require a careful immunological balance. Cytokines 
such as IL-10 and TNFα have been implicated as markers of dysregulation, but have only been 
studied at a single time point or after a pregnancy lost. Our objective was to determine normative 
patterns of serum levels of IL-10 and TNFα and their ratio throughout the first trimester in healthy 
pregnancies, and to determine if this pattern differs from pregnancy loss.
Methods: Two prospective longitudinal cohorts of gravidae including in vitro fertilization (IVF) and 
naturally conceived pregnancies with serial blood draws. Cytokines were assayed using SimplePlex. 
In the IVF cohort we monitored from the implantation day up to 6 weeks of gestation; whereas in the 
naturally conceived cohort, sample collection began at 4 weeks and throughout the whole first 
trimester.
Results:  IL-10 concentrations in normal pregnancies were significantly higher than in pregnancies 
ending in a loss starting at 6-8 weeks of gestation while TNFα concentrations were significantly lower 
in normal than in pregnancies ending in a loss starting at 3-5 of gestation weeks. The IL-10 to TNFα 
ratio in normal pregnancies was significantly higher from 4 to 9 weeks compared to pregnancies that 
were lost (t-test, p<0.05). Changes were observed before any symptoms of miscarriage were 
present. 
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Conclusions: We provide evidences of differences in early immunomodulation in healthy pregnancies 
versus those destined to end in first trimester loss. The ratio of IL-10 to TNFα rises significantly 
higher in viable pregnancies as early as 4.5 weeks compared to pregnancies loss.
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Introduction
The implantation of a semi-allogenic embryo and its ongoing development requires careful 
checks and balances in the maternal immune system. Cellular and humoral immunity are an ongoing 
area of study owing to their critical role in normal pregnancy. Alteration of cellular and humoral 
immunity might be associated with pregnancy complications, specifically recurrent implantation 
failure (RIF) and recurrent pregnancy loss (RPL)1,2. Immunologic explanations have also been 
implicated as an important reason behind early pregnancy loss in women without this history3. 
Cytokines and chemokines are a family of secreted immune modulators controlling the 
function and differentiation of both immune and non-immune cells. During pregnancy, cytokines and 
chemokines have been shown to be critical for the success of implantation, trophoblast invasion, and 
immune regulation of the maternal immune system4-6. At five days after fertilization, the process of 
implantation depends on the preparation of the uterine surface epithelium to allow a dialogue with 
and subsequent attachment of the embryonic trophectoderm. The preparation of the epithelium 
requires an inflammatory process that removes the mucin layer covering the epithelium, and the 
exposure of adhesion molecules that facilitate the attachment of the embryo7,8. After attachment, the 
blastocyst begins migration into the underlying decidua. This process is tightly regulated by immune 
cells present in the decidua, which secrete pro-inflammatory cytokines and chemokines to attract the 
blastocyst8,9. This presence is critical and depletion of any of the immune cell types has shown to be 
detrimental, resulting in fetal loss or impaired growth in animal studies10.
Excessive inflammation can also be detrimental1. Therefore, the success of implantation and 
pregnancy in general depends on the maintenance of a balance between pro-and anti-inflammatory 
signals. This balance is defined as the ratio of pro- and anti-inflammatory cytokines, and is a process 
regulated by both the maternal local environment and the implanting blastocyst. The blastocyst 
secrets immunomodulatory factors to dampen inflammation and gradually switch the environment to 
an anti-inflammatory profile as placentation is established9,11. 
Various cytokines have been examined as markers of immune dysregulation in early 
pregnancy loss, with findings of prolonged upregulation of T-helper 1(Th1) mediated pro-
inflammatory responses compared to T-helper 2 (Th2) mediated anti-inflammatory responses being 
associated with complications3,12-14. Anti-inflammatory Interleukin-10 (IL-10) and pro-inflammatory 
Tumor Necrosis Factor alpha (TNFα), both key cytokines in the cascade of immune signaling, have A
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been identified as potential markers of immune dysregulation in studies on pregnant women15-23. 
Unfortunately, the results from studies to date are inconsistent and contradictory, making it difficult to 
interpret the clinical relevance of the published data. 
Most of the reported studies have evaluated the inflammatory status at only one inconsistent 
timepoint in the first trimester and have used either nonpregnant controls as a reference, or 
compared normal pregnancies to confirmed miscarriages. In these studies, women with normal 
pregnancies show a more anti-inflammatory profile compared both to nonpregnant women and those 
with a diagnosed miscarriage13,15,16,18-20. These results do not clearly establish if the more pro-
inflammatory profile seen in diagnosed miscarriages develops before a loss is diagnosed, or if it is 
simply reflects that the immune system has returned to a normal state. Additionally, since pregnancy 
is an evolving process, the evaluation at a single time point only provides a snapshot limited to the 
specific period when the sample was taken. There is growing evidence that pregnancy represents 
physiologically distinct immunological conditions and time periods9. Therefore, looking at one single 
time cannot provide adequate information on this delicate evolving process. A longitudinal monitoring 
of cytokine profiles has not been standardized for gestational age. Establishing this is critical since 
implantation, trophoblast invasion, and placental/fetal development are active processes that 
requires a continuous adaptation of the environment. 
A major limitation on the potential clinical application of circulating cytokines for the prediction 
of pregnancy complication is the lack of standardization.  The methodology used for the evaluation of 
circulating cytokines in prior studies varies between traditional ELISAs and multiplexing platforms 
such as Luminex. The reproducibility of results between prior studies is poor, with both highly varying 
numeric results from each of these platforms and even opposite results in different studies, thus 
making it difficult to apply their findings to clinical use. Consequently, there is a need to implement a 
platform that is simple and reproducible, allowing the standardization of the normal levels of 
circulating cytokines. Simple PlexTM platform is a novel multi-analyte, automated microfluidic platform 
that allows the evaluation of cytokines and chemokines from human biological samples24. In previous 
reported studies, Simple PlexTM has shown significant advantages over traditional approaches in 
terms of low sample volume requirements, sensitivity and dynamic range, coefficient of variation and 
reproducibility; characteristics indispensable for the establishment of a diagnostic test with potential 
clinical applications24,25.
In the current study, we established a platform, Simple PlexTM , to evaluate serum cytokine 
levels in a clinical setting, demonstrating the utility of an automated, fast, simple, sensitive and A
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reproducible cytokine test. We standardized and measured the concentrations of two recognized 
markers of immune dysregulation, IL-10 and TNFα, throughout the whole first trimester, and 
demonstrated that the levels of the individual cytokines and the IL-10:TNFα ratio develops differently 
in normal pregnancies compared to pregnancies that are subsequently lost in the first trimester.  
Materials and Methods
Study population
This study includes 506 serum samples collected between 3 to 13 weeks (25 to 96 days) of 
gestation. To be able to include enough samples from the earliest timepoints in pregnancy, samples 
were collected from two prospectively followed pregnancy cohorts - women undergoing in vitro 
fertilization (IVF) treatment (n=40) and women with natural conceptions (n=102). A total of 97 women 
carried an uncomplicated full-term pregnancy (controls) and 45 women experienced a first trimester 
pregnancy loss (losses, Table 2). Samples from the IVF cohort included 83 data points for controls 
(2-6 data points for each individual) and 85 for losses (2-7 data points for each individual). The 
natural conception cohort included 270 data points for controls (3-4 data points for each individual) 
and 68 for losses (2-4 data points for each individual).
A limitation of this cohort is the lack of racial diversity.  Due to the country of enrollment (Denmark) 
the majority of the patients are Caucasian 26.  
Patient recruitment and sample collection
IVF Cohort. Recruitment of IVF patients and storage of samples was approved by the Yale 
institutional IRB with no written consent requirement (#2000021607). Patients aged 18-44 
undergoing fresh or frozen day 3 or day 5 (blastocyst) embryo transfer from October 2017 to July 
2018 were eligible for participation. Exclusion criteria were patients with chronic autoimmune disease 
(such as lupus, thyroid antibodies, ulcerative colitis, or Crohn’s disease), diabetes and hypertension 
requiring medication, endometriosis confirmed by laparoscopy, or current illness (in general, we 
excluded patients with underlying inflammatory process). We also excluded patients with prior 
losses, unless the tissue from the loss had undergone genetic testing and was determined to be 
chromosomally abnormal. Patients were asked to participate at the time of embryo transfer. Blood 
was collected by venipuncture into 10mL vacutainer tubes starting at the time of the first positive β-
hcg, 8-12 days after embryo transfer and then every 48 hours until an intrauterine pregnancy was A
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confirmed using transvaginal ultrasound, or when a pregnancy was deemed as biochemical based 
on declining β-hcg levels following an initial positive test. Samples were left at room temperature for 
60 minutes to allow for clotting and then centrifuged (Thermo Scientific Sorvall ST 16, Waltham, MA) 
at 3,000 RPM for ten minutes at room temperature. Serum was aliquoted into 1.5mL polypropylene 
RNase- and DNase-free microcentrifuge tubes and stored in -80°C freezers until ready for testing.
Naturally Conceived Cohort. The natural conception cohort was part of a larger Danish prospective 
early pregnancy cohort (the PEP cohort) recruiting women through online ads in 2016 – 2017 26. 
Healthy women with a singleton pregnancy, able to understand and sign written consent, and aged 
at least 18 years were eligible for participation. Exclusion criteria included history of recurrent 
pregnancy loss (≥3 losses, including biochemical pregnancies), any type of assisted reproductive 
techniques, uterine or tubal abnormalities assessed at the first visit, and ongoing substance abuse. 
Follow-up with serial blood draws and transvaginal ultrasound started as soon as the women 
expressed interest after a positive urine pregnancy test and continued every two weeks until 
completion of the first trimester (11–14 weeks of gestation) or a diagnosed pregnancy loss. Blood 
was collected by venipuncture into vacutainer separator tubes (BD Diagnostics, Franklin Lakes, NJ, 
USA), allowed to clot for 15 minutes at room temperature and then centrifuged (Hettich Rotina 380 
R, Andreas Hettich GmbH, Tuttlingen, Germany) for 10 min at 3500rpm at 5ºC. Serum was aliquoted 
into plastic vials equal to the IVF cohort and stored in -80°C freezers until ready for testing. 
All specimens from both cohorts were transported on liquid nitrogen to Yale University.
Simple PlexTM Immunoassay
All samples were tested using the Simple PlexTM platform (ProteinSimple, San Jose, CA), an 
automated cartridge-based immunoassay with microfluidic technology24. The cartridge is premade by 
the manufacturer according to individual needs with one to four analytes. Within the cartridge all the 
steps of a sandwich ELISA are executed automatically, thus excluding human errors, and allowing 
for fast and sensitive results. Samples are separated into parallel channels if analyzing multiple 
analytes and each analyte is analyzed in triplicate glass nanoreactors, eliminating cross-reactivity 
when multiplexing and generating a triplicate reading of each analyte. Sample concentrations 
(pg/mL) are automatically calculated by fitting RFUs to calibration curve parameters provided with 
each cartridge and adjusted for possible user defined dilution factors. The platform has been 
characterized and validated in a previously reported study24 and showed superior performance in a 
study comparing multiple platforms25. A
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Serum samples were diluted 1:2 with diluent provided by the manufacturer and 50µl of diluted 
sample was loaded into the cartridge. The performance of the platform revealed high reproducibility 
and time efficiency, with the whole process taking only 80 minutes. The data was exported to 
Microsoft Excel for analysis. The lower limits of detection were 0.46 pg/ml for IL-10 and 1.14 pg/ml 
for TNFα. The intra- and inter-assay coefficients of variance were 2.1-4.9% and 4.3% for IL-10 and 
3.3-10.4% and 6.9% for TNFα. 
Statistical analysis
The sample size was determined based on the risk of miscarriage, which is 15%. The original design 
of natural conceptions cohort had the objective to enroll 30 women who miscarried 170 
uncomplicated controls. With this sample size we can get 95% power and 5% alpha error level in an 
unpaired two-tailed test with Cohen’s D around 0.75. Even though we only collected 27 women who 
miscarried and 75 controls,  we can get 90% power in the same test.  A limitation of natural 
pregnancy cohort is that the data is usually collected after 5-7 weeks of pregnancy. We included IVF 
cohort data to get more information at early pregnancy stage and also improve the statistical power.
Before the statistical analysis, we removed 3 outliers with IL-10 larger than 20 pg/ml and 2 outliers 
with TNFα larger than 15 pg/ml. We compared differences between controls and losses at different 
phases of placentation based on gestational age using ANOVA. We then used the Locally Weighted 
Scatterplot Smoothing (LOWESS) method to estimate the changes of IL-10, TNFα, and the ratio of 
IL-10 to TNFα across gestational age for controls and losses separately. Within this model, we then 
estimated the difference of the individual cytokines and their ratio between controls and losses using 
Cohen’s D and t-test within each week. A positive Cohen’s D indicates that controls have higher 
levels than the losses, while a negative Cohen’s D indicates the controls have lower levels than the 
losses. Unlike p-value, the sample size has no influence on the statistical significance of Cohen’s D. 
Statistical analyses and graphs were done in R software 3.5.1 and GraphPad Prism v8 
(GraphPad Software Inc., San Diego, CA). A p-value less than 0.05 was considered statistically 
significant.
Results
Variations on the measurement of cytokines during pregnancy 
We looked at previous reports evaluating circulating IL-10, TNFα, and their ratio in human serum in 
early pregnancy and found 13 studies that met our inclusion criteria of comparing normal ongoing A
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pregnancies to miscarriages in the first trimester. These studies consist of the evaluation of only one 
sample from differing phases of pregnancy (Table 1). Overall, the reported values of IL-10 and TNFα 
in these studies are extremely variable, even with the same method used for analyzing samples. In 
general, IL-10 levels were found to be lower in women who went on to experience a loss when 
compared to normal pregnancies (Table 1). For TNFα, there is no clear pattern between the different 
studies. Only one study looked at the ratio of the cytokines, concluding that the profile was shifted 
toward a pro-inflammatory profile before a miscarriage happened16. These results exemplify the need 
for standardization of the methodology for evaluating circulating cytokines and the timing when the 
samples are evaluated. 
Serum levels of IL-10 and TNFα normal pregnancies and first trimester losses 
To achieve our objective of delineating the cytokine profile of pregnant women throughout the first 
trimester, we combined two cohorts: an IVF cohort where we were able to monitor the day of 
implantation and collect samples from the earliest stages of pregnancy (between 3 and 6 weeks of 
gestation), and a naturally conceived cohort, where sample collection began at 4 weeks and 
continued throughout the whole first trimester. Demographic information about the cohorts is given in 
Table 2. The IVF cohort was significantly older than the naturally conceived cohort, but otherwise 
both cohorts were similar in BMI, previous live birth, previous miscarriage, and race/ethnicity.
To test whether there is a correlation between the levels of circulating levels of IL-10 and TNFα 
throughout fetoplacental development and if this differs in normal pregnancy and pregnancies ending 
in first trimester loss, we measured the concentrations of IL-10 and TNFα in serum of these women 
and evaluated the cytokine expression pattern during established biological phases of placentation27. 
Samples were grouped into peri-implantation phase (3-5 weeks), histotrophic phase (6-8 weeks), 
and perfusion phase (9-13 weeks), based on gestational age at blood draw (Figure 1 and Table 3). In 
patients with normal pregnancies, IL-10 at peri-implantation had a mean of 2.5 pg/mL, which 
increased to 2.7 pg/mL in the histotrophic phase and 2.8 pg/mL in the perfusion phase (Fig. 1A and 
Table 3). TNFα in normal pregnancies started at an average of 5.8 pg/mL in the peri-implantation 
phase and decreased to 5.4 pg/mL in the histotrophic phase, staying steady in the perfusion phase 
at 5.5 pg/mL (Fig. 1B). In pregnancies that resulted in a loss, the IL-10 concentrations started at a 
lower level, at 2.3 pg/mL, and instead of increasing, stayed at this level in the histotrophic phase, a 
significant difference compared to the levels in normal pregnancies (p≤0.01, Fig 1A and Table 3). 
TNFα concentrations in pregnancies that resulted in a loss started significantly higher at 6.6 pg/mL in A
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the peri-implantation phase, and remained higher in the histotrophic phase at 6.2 pg/mL compared to 
the normal pregnancies (p≤0.01, Fig 1B and Table 3). 
The IL-10:TNFα ratio in normal pregnancies and first trimester losses
After determining the concentrations for IL-10 and TNF individually during early pregnancy, we 
evaluated whether the ratio of IL-10:TNF could provide better information on the balance of 
inflammation taking place during early pregnancy. In normal pregnancies, the ratio of IL-10:TNFα 
started at an average of 0.45 at peri-implantation, increased to 0.53 during the histotrophic phase, 
and remained steady at this level in the perfusion phase (Fig. 1C and Table 3). In patients with 
pregnancies resulting in a loss, we observed significant differences in the IL-10:TNF ratio compared 
to normal pregnancies. The ratio started significantly lower at peri-implantation (0.37, p=0.01), and 
remained significantly lower in the histotrophic phase (0.38, p=0.001) (Fig 1C and Table 3), whereas 
we were unable to evaluate the differences in the perfusion phase as we had to few samples from 
losses in that phase. 
Anti-/Pro- inflammatory model for normal pregnancies and first trimester losses 
We then developed a statistical model to determine whether normal fetoplacental function could be 
predicted based on the pattern of expression of these two cytokines or their ratio. As shown in Fig. 2, 
we observed that in controls, IL-10 starts at a somewhat lower level at 4 weeks gestation and 
steadily increases until week 8 (Fig. 2A). This pattern differed in loses where, although starting at a 
similar level, the IL-10 level decreased dramatically during the first weeks and never returned to the 
initial normal level thereafter (Fig 2A). In controls TNFα decreased from week 4 through 8 and then 
remained steady thereafter (Fig 2B). In losses the TNFα profile was again opposite to that in 
controls. Although starting at almost the same level as the controls, the TNFα continued to increase 
until 6-7 weeks, and remained higher than in controls for the rest of the evaluated gestational weeks. 
The differences in expression between controls and losses became clearer when looking at the ratio 
of IL-10:TNFα (Fig 2C and Table 4), with a statistically significant separation starting at week 5 
(p<0.001). In controls, the IL-10:TNFα ratio continued to rise from implantation until 8 weeks, while in 
losses the ratio behaved opposite, decreasing starting at implantation. 
When comparing IVF pregnancies and natural conception, we did not see any significant differences 
between the cohorts when comparing samples taken at similar gestational age for either the 
individual cytokines or their ratio (Fig. 3).A
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Discussion
In the present study, we describe normative longitudinal serum concentrations for IL-10 and TNFα in 
early pregnancy and for the first time illustrate how the IL-10:TNFα ratio develops throughout the 
whole first trimester and how this profile differs in pregnancies destined for loss, before a diagnosis 
or any symptoms. 
Normal pregnancy shows an early pro-inflammatory profile followed by a clear shift towards 
an anti-inflammatory profile immediately after implantation, characterized by an increase in IL-10, 
decrease in TNFα, and increasing IL-10:TNFα ratio. Interestingly, pregnancy loss was associated 
with a failure in this shift, with no increase in neither IL-10 alone nor in the IL-10:TNFα ratio. These 
findings provide evidence in support for the relevance of the shift from  inflammation to anti-
inflammation necessary for the maintenance of the pregnancy9 and support earlier findings defining 
normal pregnancy as an anti-inflammatory condition27,28. Furthermore, our findings for the first time 
illustrate that the shift happens very early, right after implantation.
In both normal pregnancies and losses, the TNFα level was highest at early implantation, 
which is in line with prior evidence of a pro-inflammatory profile supporting implantation5,8,10. In 
pregnancies ending in a loss TNFα was higher than in normal pregnancies at the earliest phase 
(Figure 1), possibly reflecting either excessive inflammation or a disturbed local immune education 
leading to the failure to shift the balance towards a more anti-inflammatory profile reflected by the 
rising IL-10:TNFα ratio seen in normal pregnancies. 
Prior studies looking at IL-10 and TNFα as predictive biomarkers contribute to the knowledge 
of immune balance, but studies are small and conclusions are based on single samples taken at 
differing timepoints during the first trimester, with inconclusive results (Table 1). IL-10 has previously 
been shown to be comparatively lower and TNFα comparatively higher in patients who have just 
been diagnosed with miscarriage17 and in patients with threatened miscarriage who go on to 
miscarry18 compared to normal pregnancies. In at least two studies, it has been shown that in both 
patients with and without a history of RPL, IL-10 is higher in pregnancies that go on to have live 
births compared to pregnancies that don’t15,19. Conversely, one study found that the IL-10 
concentration is significantly lower in pregnancies that go on to have live births20. In patients who had 
undergone IVF, TNFα levels in the 5th week of gestation were significantly higher in women who 
went on to have a pregnancy loss21 and also in women who had already miscarried, TNFα levels A
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were elevated when compared to women with healthy pregnancies22. Alternately, one study found no 
differences in either IL-10 or TNFα concentrations between patients in the first trimester who went on 
to have a healthy pregnancy versus those who had a miscarriage23. A meta-analysis comparing RPL 
patients to patients with normal pregnancy found that TNFα was higher in the recurrent pregnancy 
loss patients, but not all studies included in the meta-analysis looked at pregnant patients, sample 
timing was inconsistent between evaluated studies and some studies evaluated the RPL patients 
after a diagnosed loss, not before16. These studies, looking at only one time point and with varying 
methodologies and definitions of controls and cases do not clearly delineate the distinct 
immunological time periods represented by the first trimester. 
The process of implantation and placentation is a continuum of crosstalk between the 
maternal and fetal side. At five days after fertilization, it is known that the epithelium must 
demonstrate receptivity to the invading trophoblast by secreting pro-inflammatory cytokines and 
protease inhibitors10,11,29, and in response the trophoblast indirectly stimulates Th2 cytokine 
production3. Up to 4.5 weeks gestation, the crosstalk between the embryo and the maternal uterine 
environment is suspected largely to focus on this invasion. This correlates with our finding that in 
normal pregnancy at this time, the serum IL-10:TNFα ratio is balanced and similar in pregnancies 
that are destined to miscarry. In our study, miscarriages have an unchanged IL-10:TNFα ratio at 5 
weeks, whereas normal pregnancies have an increasing ratio. The profiles take a different direction 
from hereon. By 6 weeks, implantation is completed and the embryo relies primarily on glandular 
nutrition while the process of vascularization begins, a process requiring continued migration of cells 
and modulation of the environment. By 9 weeks the early blood supply is established and along with 
that oxidative tension gradually increases, yet again posing different challenges for the embryo30,31. 
Since the mechanism of trophoblast invasion and blood vessel recruitment is not clearly understood 
but is thought to rely at least partially on cytokine signaling, delineating the timing of cytokine 
aberrations in these different phases in both patients with normal pregnancy and early miscarriage is 
important.
Our study improves upon the foundation established by past research by following 
longitudinal changes in these serum biomarker concentrations throughout the first trimester, and 
enrolling subjects prior to any signs or symptoms of miscarriage. By utilizing IVF patients, we were 
able to obtain the earliest information possible. To our knowledge this is also the first study 
comparing IVF pregnancies and natural conceptions and we did not see any significant differences 
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between the cohorts when comparing samples taken at similar gestational age for either the 
individual cytokines or their ratio (Fig. 3).
 The platform used to analyze the samples displayed a high sensitivity, with readings from all 506 
samples being within the detection rate and with low variability. The fully automatic design enabled 
fast analysis and excluded human errors. 
A clear weakness of the study was the lack of samples before conception. We were unable to 
assess how the cytokine levels and ratio change after conception. Also, as most losses were 
diagnosed by week 8, our samples size in the losses group from week 9 onwards is insufficient in 
demonstrating significant differences between controls and losses in late first trimester, although the 
trends were similar. Furthermore, we only had access to histologic evaluation or genetic testing 5/45 
losses (11%), and therefore cannot be certain that all losses were chromosomally normal. This may 
be of importance as others have shown differences in inflammation between losses with normal and 
abnormal karyotype32. 
Much of prior studies have focused on immunological differences between healthy women 
and women with repeated pregnancy losses or in a population where miscarriage has already been 
diagnosed15,33,34. Here we show that the immunological profile differs in healthy women with 
subsequent pregnancy loss compared to normal pregnancies, before any symptoms. Standardizing 
and demonstrating this difference longitudinally in first trimester serum samples from seemingly 
healthy women fuels further research and strives towards finding immunologic predictive tests. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Acknowledgements
The authors wish to thank the clinical and laboratory team of the Department of Obstetrics 
Gynecology and Reproductive Sciences at Yale University . We also would like to thank the Joey 
Guy for reviewing the manuscript.
Authors’ roles
G.M., L.P. and M.P. designed the study and interpreted the results. K.K. and S.S performed data 
analysis and wrote the article. G.P. performed statistical analysis and model design. P.A. performed 
cytokine assays.  S.G, JFP and EL contributes with patient’s enrollment, sample collection and data 
collection.  All authors participated in data analysis and critical reading and editing of the article. All 
authors approved the final version of the article.
Funding
No funding was obtained.
Conflict of interest
None declared
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
References
1. Krieg S, Westphal L. Immune Function and Recurrent Pregnancy Loss. Semin Reprod Med. 
2015;33(4):305-312.
2. Shetty S, Ghosh K. Anti-phospholipid antibodies and other immunological causes of recurrent foetal 
loss--a review of literature of various therapeutic protocols. Am J Reprod Immunol. 2009;62(1):9-24.
3. Kwak-Kim J, Bao S, Lee SK, Kim JW, Gilman-Sachs A. Immunological modes of pregnancy loss: 
inflammation, immune effectors, and stress. Am J Reprod Immunol. 2014;72(2):129-140.
4. Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal 
lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. 
Hum Reprod. 2000;15(3):713-718.
5. Boomsma CM, Kavelaars A, Eijkemans MJ, et al. Endometrial secretion analysis identifies a cytokine 
profile predictive of pregnancy in IVF. Hum Reprod. 2009;24(6):1427-1435.
6. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J. Expression of intracellular Th1 
and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET 
or normal pregnancy. Am J Reprod Immunol. 2002;48(2):77-86.
7. Dekel N, Gnainsky Y, Granot I, Mor G. Inflammation and implantation. Am J Reprod Immunol. 
2010;63(1):17-21.
8. Dekel N, Gnainsky Y, Granot I, Racicot K, Mor G. The role of inflammation for a successful 
implantation. Am J Reprod Immunol. 2014;72(2):141-147.
9. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev 
Immunol. 2017;17(8):469-482.
10. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune 
system at the implantation site. Ann N Y Acad Sci. 2011;1221:80-87.
11. Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 
2010;63(6):425-433.
12. Tripathi S, Guleria I. Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the 
fetus. Biomed J. 2015;38(1):25-31.
13. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am 
J Reprod Immunol. 2010;63(6):601-610.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
14. Makrigiannakis A, Petsas G, Toth B, Relakis K, Jeschke U. Recent advances in understanding 
immunology of reproductive failure. J Reprod Immunol. 2011;90(1):96-104.
15. Jenkins C, Roberts J, Wilson R, MacLean MA, Shilito J, Walker JJ. Evidence of a T(H) 1 type response 
associated with recurrent miscarriage. Fertil Steril. 2000;73(6):1206-1208.
16. Zhang C, Deng X, Zhang X, et al. Association between Serum TNF-alpha Levels and Recurrent 
Spontaneous Miscarriage: A Meta-analysis. Am J Reprod Immunol. 2016;75(2):86-93.
17. Calleja-Agius J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and cytokine 
levels in threatened miscarriage. Gynecol Endocrinol. 2011;27(2):121-127.
18. Calleja-Agius J, Muttukrishna S, Pizzey AR, Jauniaux E. Pro- and antiinflammatory cytokines in 
threatened miscarriages. Am J Obstet Gynecol. 2011;205(1):83 e88-16.
19. Paradisi R, Maldini-Casadei M, Boni P, Busacchi P, Porcu E, Venturoli S. T-helper 2-cytokine levels in 
women with threatened abortion. Eur J Obstet Gynecol Reprod Biol. 2003;111(1):43-49.
20. Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I. Serum levels of pro- and 
anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. 
Mediators Inflamm. 1998;7(2):69-72.
21. Freis A, Schlegel J, Daniel V, Jauckus J, Strowitzki T, Germeyer A. Cytokines in relation to hCG are 
significantly altered in asymptomatic women with miscarriage - a pilot study. Reprod Biol Endocrinol. 
2018;16(1):93.
22. Verma P, Verma R, Nair RR, et al. Altered crosstalk of estradiol and progesterone with Myeloid-
derived suppressor cells and Th1/Th2 cytokines in early miscarriage is associated with early 
breakdown of maternal-fetal tolerance. Am J Reprod Immunol. 2019;81(2):e13081.
23. Barrientos G, Fuchs D, Schrocksnadel K, et al. Low levels of serum asymmetric antibodies as a marker 
of threatened pregnancy. J Reprod Immunol. 2009;79(2):201-210.
24. Aldo P, Marusov G, Svancara D, David J, Mor G. Simple Plex() : A Novel Multi-Analyte, Automated 
Microfluidic Immunoassay Platform for the Detection of Human and Mouse Cytokines and 
Chemokines. Am J Reprod Immunol. 2016;75(6):678-693.
25. Fischer SK, Carrasco-Triguero M, Hong K, et al. Commercial biomarker assays: friend and foe. 
Bioanalysis. 2016;8(22):2351-2362.
26. Friis Petersen J, Friis-Hansen LJ, Jensen AK, Nyboe Andersen A, Lokkegaard ECL. Early pregnancy 
reference intervals; 29 serum analytes from 4 to 12 weeks' gestation in naturally conceived and A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
uncomplicated pregnancies resulting in live births. Clinical chemistry and laboratory medicine : CCLM 
/ FESCC. 2019.
27. Nicholson R, ebrary Inc. The placenta development, function and diseases. In: An overview 
ofdevelopment, functions and diseases of the placenta. Hauppauge, N.Y.: Nova Science Publishers, 
Inc.,; 2013: http://site.ebrary.com/lib/yale/Doc?id=10693655.
28. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent 
spontaneous abortion. JAMA. 1995;273(24):1933-1936.
29. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E. Maternal Th1- and Th2-
type reactivity to placental antigens in normal human pregnancy and unexplained recurrent 
spontaneous abortions. Cell Immunol. 1999;196(2):122-130.
30. Roberts VHJ, Morgan TK, Bednarek P, et al. Early first trimester uteroplacental flow and the 
progressive disintegration of spiral artery plugs: new insights from contrast-enhanced ultrasound and 
tissue histopathology. Hum Reprod. 2017;32(12):2382-2393.
31. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol 
Investig. 2004;11(6):342-352.
32. Yamada H, Morikawa M, Furuta I, et al. Circulating cytokines during early pregnancy in women with 
recurrent spontaneous abortion: decreased TNF-alpha levels in abortion with normal chromosome 
karyotype. Hokkaido Igaku Zasshi. 2004;79(3):237-241.
33. Arslan E, Colakoglu M, Celik C, et al. Serum TNF-alpha, IL-6, lupus anticoagulant and anticardiolipin 
antibody in women with and without a past history of recurrent miscarriage. Arch Gynecol Obstet. 
2004;270(4):227-229.
34. Calleja-Agius J, Jauniaux E, Muttukrishna S. Placental villous expression of TNFalpha and IL-10 and 
effect of oxygen tension in euploid early pregnancy failure. Am J Reprod Immunol. 2012;67(6):515-
525.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Figure Legends.
Figure 1. Levels of IL-10 (A), TNFα (B) and their ratio (C) shown according to biological phases of 
placentation. 4-5 weeks refers to the peri-implantation phase, 6-8 weeks to the histotrophic phase, 
and 9-13 weeks to the perfusion phase. Data presented as mean+/-SD. *p≤0.01, **p<0.001
Figure 2. The changes of IL-10 (A), TNFα (B) and their ratio (C) across gestational age. The line 
represents the mean estimation by LOWESS and the colored areas the 95% confidence intervals of 
the mean estimation. Only the ratio is significantly different between the groups (p<0.05)
Figure 3. The changes of IL-10 (A), TNFα (B) and their ratio (C) in IVF pregnancies and natural 
conceptions. There is no difference between the cohorts in normal pregnancies. In IVF pregnancies 
ending in a loss both IL-10 and TNF are higher than in natural conceptions ending in a loss, but the 
ratio does not differ between the cohorts.  * p=0.009 for IL-10 and *p=0.04 for TNF
. 
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Table 1. Studies comparing serum IL-10 (pg/ml) or TNFα (pg/ml) levels or their ratio in 1st trimester normal pregnancy and pregnancy loss. 
IL-10     Controls Cases 
Reference Groups compared Controls/Losses Blood drawn Gestational age Mean  Median  Range Mean  Median  Range Method 
Jenkins et al 2000 Healthy women- 
Normal outcome vs. loss 
10/10 Before loss 5-10 12138 (SD) - - 102 54 (SD) - - ELISA 
Jenkins et al 2000 * RPL patients- 
Normal outcome vs. loss 
5/5 Before loss 5-10 175 - 80-340  55  - 30-80  ELISA 
Barrientos et al 2009 * Healthy women- 
Normal outcome vs. loss 
42/42 Before loss 4-12 1115 (SEM) - - 56 (SEM) - - ELISA 
Calleja-Agius et al 2011-1 *+ 1
st
 trimester bleeding –  
Normal outcome vs. loss 
27/53 Before loss 7-10 4.5 - - 1.5  - - Multiplex 
Vassiliadis et al 1998 Healthy women-  
Normal outcome vs. loss 
19/19 After loss <13 77070 (SEM) - - 86060 (SEM) - - ELISA 
Paradisi et al 2000 * Healthy women-  
Normal outcome vs. loss  
14/14 After loss 8-11 
 
4.41.4 (SD) - 2-7.5 2.01.1 (SD) - 1-5  ELISA 
Calleja-Agius et al 2011-2* ++ Healthy women-  
Normal outcome vs. loss 
8/11 After loss <13 - 4.5  0-15 - 3.5  0-12.5 Multiplex 
Verma et al 2018 *** Healthy women-  
Normal outcome vs. loss 
20/20 After loss 7-12 16.56±2.015 (SD) - 6-33  17.411.14 (SD) - 10-34 Multiplex 
TNFα     Controls   Cases    
Reference Groups compared Controls/Losses Blood drawn Gestational age Mean  Median  Range Mean  Median  Range Method 
Barrientos et al 2009 * Healthy women- 
Normal outcome vs. loss 
42/42 Before loss 4-12 1818 (SEM) - - 18 15 (SEM) - - ELISA 
Calleja-Agius et al 2011-1 *+ 1
st
 trimester bleeding –  
Normal outcome vs. loss 
27/53 Before loss 7-10 2.5 - - 1.5 - - Multiplex 
Freis et al 2018 IVF patients-  
Normal outcome vs. loss 
22/17 Before loss 5 5.000.26 (SEM) - - 5.11 0.40 - - Multiplex 
Calleja-Agius et al 2011-2 * Healthy women-  
Normal outcome vs. loss 
8/11 After loss <13 - 4.5  0.5-6.5 - 0.5 0.5-13 Multiplex 
Verma et al 2018 Healthy women-  20/20 After loss 7-12 91.84±16.01 (SD) - 10-320  127.09.19 - 70-230 Multiplex A
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Normal outcome vs. loss 
* These studies only displayed values graphically, values estimated from figures 
+ This study reported the mean TNFα:IL-10 ratio for normal pregnancy (1) and women who miscarried later (4) 
++ This study reports an elevated TNFα:IL-10 ratio in pregnancies that had miscarried, no value given 
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Table 2. Patient demographics 
 IVF Natural conceptions 
 Controls 
(n=22) 
Losses 
(n=18) 
Controls 
(n=75) 
Losses 
(n=27) 
Age (meanSD)* 35.14.4 37.14.2 28.1  3.3 30.54.7 
BMI (meanSD) 25.24.9 25.63.2 24.2  4.5 25.65.6 
Previous live birth n(%) 7 (31.8) 2 (11.1) 28 (37.3) 12 (44) 
Previous miscarriage 
n(%) 
4 (18.2) 2(11.1) 9 (12.0) 6 (22) 
Caucasian  73% 78% 100% 100% 
*The natural conception cohort was younger, p<0.01. 
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Table 3. Levels of IL-10, TNFα and their ratio shown at the different biological phases of placentation. 
 Controls Losses 
Peri-implantation 
4-5 weeks 
N=123 
Histiotrophic phase 
6-8 weeks 
N=110 
Perfusion phase 
9-13 weeks 
N=120 
Peri-implantation 
4-5 weeks 
N=93 
Histiotrophic phase 
6-8 weeks 
N=42 
Perfusion phase 
9-13 weeks 
N=15 
IL-10 (pg/ml) Mean  SD 2.531.28 2.730.84 2.821.10 2.350.80 2.340.77 2.470.85 
 Median 2.31 2.56 2.54 2.28 2.18 2.11 
 Range 0.75-10.61 1.53-6.68 1.41-9.85 0.66-5.15 1.03-5.16 1.60-4.73 
TNFα (pg/ml) Mean  SD 5.76177 5.411.42 5.461.49 6.602.00 6.231.46 5.561.57 
 Median 5.56 5.14 5.41 6.40 6.10 5.63 
 Range 1.51-11.33 1.86-10.01 2.36-11.18 2.24-11.23 2.53-9.52 2.41-8.40 
IL-10:TNFα (ratio)  Mean  SD 0.450.19 0.530.19 0.530.20 0.370.11 0.380.12 0.480.21 
 Median 0.41 0.50 0.51 0.36 0.36 0.40 
 Range 0.15-1.16 0.18-1.22 0.19-1.69 0.16-0.63 0.23-0.92 0.29-1.11 
Significant p-values can be found in Figure 2, which shows this data graphically.  
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Table 4. Statistical comparison between controls and losses using Cohen's D (p-values). 
A positive Cohen’s D indicates that controls have higher levels than the losses, while 
a negative Cohen’s D indicates the controls have lower levels than the losses.  
Pregnancy Week IL-10 TNF𝝰 IL-10:TNF𝝰 
4 0.02 (0.90) -0.32 (0.10) 0.26 (0.140) 
5 0.55 (0.02) -0.34 (0.15) 0.93 (2e-04) 
6 0.41 (0.11) -0.54 (0.07) 0.80 (8e-04) 
7 0.58 (0.11) -0.54 (0.14) 0.87 (0.008) 
8 0.59 (0.06) -0.65 (0.04) 1.00 (6e-05) 
9 0.64 (0.04) 0.29 (0.52) 0.40 (0.245) 
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